Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

About Theranexus

Theranexus is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Thanks to its knowledge of neuron and glial cell interactions, THERANEXUS is a pioneer in the design and combination of approved substances and has a solid and diversified portfolio of drug candidates in clinical-phase testing. The company’s combined drug repurposing strategy based on a solid commercial footing and a capability to rapidly demonstrate its clinical worth, enables it to produce different high-value-added proprietary drug candidates, significantly reduce development time and costs, and considerably increase the chance of its drugs reaching the market. Accordingly, THERANEXUS is well-positioned in several indications, including for Parkinson’s and Batten disease, for which there is currently no treatment available. Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).

THERANEXUS publishes its cash position as of June 30 2021 and presents an update on the progress of its main programs

08/07/2021
Download PDF File (1546Ko)

Minutes of the combined general meeting of 16 June 2021

16/06/2021
Download PDF File (227Ko)

2020 full-year results and update on the progress of main programs

07/04/2021
Download PDF File (1443Ko)

THERANEXUS extends the capabilities of Neurolead, its active agent screening platform, to autophagy and neurological lysosomal storage disorders

09/03/2021
Download PDF File (326Ko)

THERANEXUS presents an update on the progress of its main programs and announces its cash position as of 31 December 2020

18/01/2021
Download PDF File (538Ko)